Expert Interview
Digging into Seagen's Phase 2 Mountaineer trial (Tucatininb + Trastuzumab) for patients with HER2+ mCRC
Ticker(s): SGENInstitution: Henry Ford & Wayne State University
- Director, Gastrointestinal Oncology, Medical Director, Research and Clinical Care Integration, Henry Ford Cancer Institute & Professor of Medicine, Wayne State University School of Medicine.
- Internationally renowned medical oncologist specializing in gastrointestinal cancers who has led numerous breakthroughs in the areas of pancreatic and neuroendocrine tumors.
- Primary research focus is the oversight of Phase 1 and 2 clinical trials of novel therapeutic agents and therapeutic combinations on patients with pancreatic, gastro-esophageal, liver, and colorectal cancer.
Could you first give a brief introduction of your clinical expertise and details about your practice setting?
Added By: ben_adminHow many patients with colorectal cancer do you treat? Do you treat any with metastatic disease? What % is metastatic?
Added By: ben_adminCan you talk about your familiarity with HER2 medications?
Added By: ben_adminWhen you get a new patient or for current patients, do you know their HER2 status already? Do you have to order NextGen sequencing?
Added By: ben_adminWant to focus on the current standard of care and your algorithm for selecting medications. What are you typically giving patients right now on the front line? What goes into this decision?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
